Compare Raymond James Financial, Inc. (RJF) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Raymond James Financial, Inc. vs 10X Genomics Inc — how do they compare? Raymond James Financial, Inc. trades at $175.81 (market cap $33.96B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: Raymond James Financial, Inc. is far larger — about 4× 10X Genomics Inc's market cap, and Raymond James Financial, Inc. pays a 1.22% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| RJF | TXG | |
|---|---|---|
Market Cap | $33.96B | $8.55B |
Sector | Financials | Health |
52-Week High | $181.18 | $67.29 |
52-Week Low | $140.89 | $11.34 |
Dividend Yield | 1.22% | — |
Enterprise Value | — | $8.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Raymond James Financial (RJF) trades at $176.55, down 0.98% on the day, with a bullish earnings trend after beating estimates for three consecutive quarters. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Recent Q3 2026 results showed record revenues of $3.93 billion, up 16% year-over-year, driven by wealth management growth and investment banking recovery.
RJF presents a compelling investment case with strong fundamentals and analyst support, though technical indicators suggest near-term caution. The consensus price target of $184.11 implies 4.3% upside potential, with no sell ratings among 25 analysts. Key risks include rising expenses and capital markets volatility, while the company's advisor recruitment momentum and dividend payments provide stability.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
